about
Evaluating a Collaborative Approach to Improve Prior Authorization Efficiency in the Treatment of Hepatitis C VirusA Review Exploring the Relationship Between Nursing Home Staffing and Antipsychotic Medication Use.Innovative patient care practices using social media.Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?Beliefs and behaviors of professionally engaged pharmacists.No filter: A characterization of #pharmacist posts on Instagram.Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.APhA2009 House of Delegates: serving the association and the profession.Measuring Up – Defining the Quality of PharmD Programs.Evaluating the Changing Financial Burdens for Graduating Pharmacists.Examining patient-provider relationship (PPR) quality and patient activation in the Medicare population.Service description and analysis for an interprofessional discharge clinic within a primary care practice.Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?Optimizing the role of pharmacy technicians in patient care settings: Measuring pharmacy technician impact on desired outcomes.Implementing a Health Confidence Tool at Time of DischargePenicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysisBurden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population.Pharmacy practice around the worldRescheduling of combination hydrocodone products: problems for long-term care practitionersUsing 340B drug discounts to provide a financially sustainable medication discharge serviceEstimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness AnalysisWhat Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and AltruismReal World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
P50
Q33879348-3117FE5B-4AFB-4F2D-A672-95D5121157E9Q36389719-DE97FB85-58B9-4016-A52C-1DF3E54316B2Q38414124-5587110A-2608-4EB6-8AEE-66ACD08ED3A9Q38638095-8FFF360B-8C1C-4A33-BC22-2840533FD760Q38675366-2567F640-A75A-4F11-8857-79A7C476EA94Q38852618-164B1966-7A75-4A75-9764-681F67AB9833Q38924572-2EAA0996-0120-4F6C-BC0B-A4D358119150Q40191626-31EBF024-2B49-4258-802F-CB75B00BE3F7Q43369644-DFCB094D-5E68-4CC2-8999-FCE979D88CD2Q47125025-576FC0C9-BBAD-49ED-8ADE-FCF7FC991795Q47147542-DE05046C-815B-4935-89C2-57BD243F9369Q47418972-BF5B4158-24AC-4CD4-A8C4-989C27280D64Q47908927-D9546949-CDFE-4341-82F9-F76A14FC579EQ48121988-7B31C5AD-C7A4-4083-A94B-A68040F0F505Q49380437-E73226BC-EEFA-44B7-B04B-CEED81CE3F3BQ58098168-82EE58B5-9B2D-47D9-A1C5-AF3BAF3240C5Q60920032-29FDCFCA-945F-4EF3-896E-ED0922A01F96Q64899790-E85361C5-2608-47AB-BAB1-E58C2F27C8F6Q83303254-0A492358-0034-400D-B645-CECB64738FD2Q86536748-37E49381-5D71-486D-8F77-3DAFDB4D2FA4Q88239620-9974FEBD-3A45-4DCD-A405-947CAD54E6BBQ88646683-29F9ADF4-CC9A-4A37-A03D-ED337FDAD21CQ91589837-F59DD4B6-64CF-44D6-AD29-F5966645678CQ92192389-562FB2E8-9513-4546-B7B9-0C904E96E402Q96349877-2B99DF01-F399-4A4C-8296-86BEA8802E95
P50
description
investigador
@es
researcher
@en
name
Joey Mattingly
@en
type
label
Joey Mattingly
@en
prefLabel
Joey Mattingly
@en
P31
P496
0000-0001-7786-5780